What TruHealth Is Actually Measuring — and Why It's Not Just Another Blood Test

What TruHealth Is Actually Measuring — and Why It's Not Just Another Blood Test

It's a question that comes up on nearly every report review call: "Their serum vitamin D was normal. Why does TruHealth show it as low?"

It's a fair question, and the answer gets to the heart of what makes TruHealth different. TruHealth isn't trying to replicate standard bloodwork. It's offering a different biological lens: a methylation-based view of how the body has been functioning over time.

A different kind of measurement

Serum labs measure what's circulating in the bloodstream at a specific point in time. TruHealth EBPs do something different: they use DNA methylation patterns to predict biomarker values based on the body's longer-term biological state.

DNA methylation is the most studied epigenetic mechanism. It refers to chemical tags on DNA that are known to regulate gene expression. These patterns are dynamic and respond to what the body experiences over time. TruHealth reads hundreds of thousands of methylation sites, then uses machine learning models trained on cohorts with paired serum and methylation data to generate epigenetic biomarker predictions.

The key distinction is simple:

• A serum test asks: What is in this patient's bloodstream right now?
• An EBP asks: What does this patient's methylation pattern suggest about their biological state over time?

Both questions are valid, but don't move in lockstep. When they diverge, that difference may be the most clinically useful part of the report.

The Vitamin D example

Consider a patient whose serum vitamin D is 48 ng/mL — well within normal range — while their TruHealth vitamin D EBP is flagged as low.

This is where the distinction becomes clinically meaningful.

Serum vitamin D reflects circulating levels at the time of the blood draw. It can change relatively quickly with sun exposure, supplementation, seasonality, or recent behavior. The EBP is looking at functional vitamin D status: whether the patient's methylation pattern resembles that of someone with lower levels, over a longer biological window.

That distinction matters. A patient may have adequate circulating vitamin D today while still showing methylation-based signs that their biology has not been responding to, utilizing, or reflecting Vitamin D sufficiency in the same way. That does not mean the serum test is wrong. It means the two tests are surfacing different information.

In practice, this should be treated as a hypothesis generator: something to interpret alongside symptoms, supplementation history, seasonality, medication use, related biomarkers, and the broader TruHealth pattern.

The CRP example: why the time horizon matters

Inflammation is where this concept becomes especially clear.

Standard CRP is highly responsive to acute events. An infection, hard workout, injury, poor sleep, or short-term stressor can send CRP up, and it may normalize within days. That makes CRP useful, but it also means a single result can be heavily influenced by what happened recently.

A methylation-based inflammatory signal is less about today's spike and more about the body's longer-term inflammatory pattern. A patient might have normal CRP at the time of testing but still show an elevated epigenetic inflammation signal that reflects a more chronic underlying burden.

This is why methylation-based inflammatory predictors can sometimes show stronger associations with long-term outcomes than directly measured CRP. They are not just capturing the acute reading — they may be capturing the biological trend.

Why EBPs can be more predictive than the direct measurement

In some domains, methylation-based predictors are more strongly associated with future health outcomes than the direct measurements they are trained to predict.

Telomere length is a good example. Directly measured telomere length has long been used as a cellular aging marker, but it can be noisy and variable. A well-established methylation-based telomere length predictor was shown to track more consistently with chronological aging and displayed stronger associations with mortality and cardiovascular outcomes than directly measured telomere length.

The broader principle is that methylation patterns can capture a more integrated biological signal. They reflect how the body has been functioning across time, not just what was measurable in a single compartment on a single day.

How to use this in practice

TruHealth is not a replacement for standard labs. It's a complementary layer.

When an EBP and a serum result don't match, the right response is not to ask which test is "wrong." The better question is: What could explain the difference between a point-in-time circulating measurement and a longer-term methylation-based signal?

A few practical ways to interpret discordance:

• Review the time horizon: could the serum result reflect a recent change, acute event, or short-term intervention?
• Look for supporting patterns: are related EBPs flagged in a way that tells a coherent biological story?
• Consider clinical context: symptoms, medications, supplementation, lifestyle changes, and recent illness may all matter.
• Use the result to guide follow-up: the EBP should help prioritize what to investigate, monitor, or discuss next.

When a patient asks why their TruHealth result doesn't match their blood test, the simplest answer is: they are not measuring the same thing. One reflects what's circulating at a point in time. The other reflects a methylation-based biological pattern that may capture a longer-term signal. When those pictures diverge, that's worth understanding — not dismissing.